Drugs Information:
Regorafenib
Basic Information
|
|
||
| ID | DDInter1576 | |
| Drug Type | small molecule | |
| Molecular Formula | C21H15ClF4N4O3 | |
| Molecular Weight | 482.815 | |
| CAS Number | 755037-03-7 | |
| Description | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. | |
| ATC Classification | L01EX05 | |
| IUPAC Name | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide | |
| InChI | FNHKPVJBJVTLMP-UHFFFAOYSA-N | |
| Canonical SMILES | CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1 | |
| Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB Wikipedia ChEMBL ZINC | |
Interactions with
Regorafenib
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|